ArticleJournal of hepatology2017
HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
Article in Journal of hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 273 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
273 citing papers in PubMed, 3 syntheses or guidelines pooled it, 569 citations in OpenAlex.
- Prevention, surveillance, and early detection of hepatocellular carcinoma - a Brazilian multidisciplinary consensus.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026Guideline
- HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis.Hepatology (Baltimore, Md.) · 2022Pooled it
- Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.Hepatology (Baltimore, Md.) · 2020Guideline
- Risk of type 2 diabetes mellitus after treatment with direct-acting antivirals for hepatitis C virus in people with HIV.AIDS (London, England) · 2026Observational
- Chronic Viral Hepatitis Screening Inequities Across Florida Federally Qualified Health Centers.Journal of racial and ethnic health disparities · 2026Article
- Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Health care providers' perspectives on barriers and enablers to providing hepatitis C screening and treatment for immigrants in Canada: A theory-informed qualitative study.Canadian liver journal · 2026Article
- Hepatitis A to E in People with HIV: A Virus-Specific Review of Prevention and Treatment.Infectious diseases and therapy · 2026Review
- Impact of sustained virological response on prognosis after hepatectomy for hepatitis C-related hepatocellular carcinoma: a retrospective cohort study.BMC infectious diseases · 2026Article
- Primary liver cancer in Georgia: Seven years' experience following the launch of the Hepatitis C Elimination Program, 2015-2022.PloS one · 2026Article
- 2025 KASL clinical practice guidelines for management of hepatitis C.Clinical and molecular hepatology · 2026Article
- European Code Against Cancer, 5th edition - cancer-causing infections and related interventions.Molecular oncology · 2026Review
- Etiology-Driven Mouse Models of Hepatocellular Carcinoma: Paving the Way for Precision Oncology.Journal of hepatocellular carcinoma · 2026Review
- Economic evaluation of biomarker-based surveillance for Hepatocellular Carcinoma in Thai patients with Compensated Liver Cirrhosis.PloS one · 2026Article
- Rates and Factors Associated With Hepatocellular Carcinoma Diagnosis, Stage, Treatment, and Survival.Gastro hep advances · 2026Article
- Transient elastography and fibrosis-4 index as predictors of hepatocellular carcinoma in hepatitis C virus patients with sustained virological response.World journal of gastroenterology · 2025Article
- Cause-specific mortality following sustained virologic response in hepatitis C patients treated with direct-acting antivirals: a standardized mortality ratio analysis.Scientific reports · 2025Article
- A novel scoring system to identify patients at low risk for hepatocellular carcinoma five years after DAA-Induced sustained virological response: a retrospective cohort study.BMC gastroenterology · 2025Article
- Gut microbiome dysbiosis in hepatocellular carcinoma patients with persistent HCV viremia versus viral clearance: a cross-sectional study.Gut pathogens · 2025Article
- Chemoprevention of hepatocellular carcinoma.Hepatology communications · 2025Review
213 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsIt is unclear whether direct-acting antiviral (DAA) treatment-induced sustained virologic response (SVR) reduces the risk of hepatocellular carcinoma (HCC) in patients with HCV infection. Therefore, in the current study, our aim was to determine the impact of DAA-induced SVR on HCC risk.
methodsWe identified 62,354 patients who initiated antiviral treatment in the Veterans Affairs (VA) national healthcare system from 1 January 1999 to 31 December 2015, including 35,871 (58%) interferon (IFN)-only regimens, 4,535 (7.2%) DAA + IFN regimens, and 21,948 (35%) DAA-only regimens. We retrospectively followed patients until 15 June 2017 to identify incident cases of HCC. We used Cox proportional hazards regression to determine the association between SVR and HCC risk or between type of antiviral regimen (DAA-only vs. DAA + IFN vs. IFN-only) and HCC risk.
resultsWe identified 3,271 incident cases of HCC diagnosed at least 180 days after initiation of antiviral treatment during a mean follow-up of 6.1 years. The incidence of HCC was highest in patients with cirrhosis and treatment failure (3.25 per 100 patient-years), followed by cirrhosis and SVR (1.97), no cirrhosis and treatment failure (0.87), and no cirrhosis and SVR (0.24). SVR was associated with a significantly decreased risk of HCC in multivariable models irrespective of whether the antiviral treatment was DAA-only (adjusted hazard ratio [AHR] 0.29; 95% CI 0.23-0.37), DAA + IFN (AHR 0.48; 95% CI 0.32-0.73) or IFN-only (AHR 0.32; 95% CI 0.28-0.37). Receipt of a DAA-only or DAA + IFN regimen was not associated with increased HCC risk compared with receipt of an IFN-only regimen.
conclusionsDAA-induced SVR is associated with a 71% reduction in HCC risk. Treatment with DAAs is not associated with increased HCC risk compared with treatment with IFN. LAY SUMMARY: It was unclear whether direct-acting antiviral treatment-induced sustained virologic response reduces the risk of liver cancer in patients with HCV infection. We demonstrated that eradication of HCV infection with direct-acting antiviral agents reduces the risk of liver cancer by 71%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.